Clinical trials: Systemic Autoimmune Diseases
Rheumatoid Arthritis, Ankylosing Spondylitis
Employment and Arthritis: Making it Work
The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, Systemic, Psoriatic Arthritis
- Trial name
- MIW (NCT01852851)
- Testing
- Employment and Arthritis: Making it Work
- Where
- Canada
- Volunteers
- 528 people
- Sponsor
- University of British Columbia
Churg Strauss Syndrome
Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
Churg-Strauss syndrome is a rare type of systemic vasculitis which occurs almost exclusively in patients with asthma and which is characterized by prominent blood and tissue eosinophilia.
- Trial name
- MEPOCHUSS (NCT00716651)
- Testing
- mepolizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Schleswig-Holstein
Chronic Inflammatory Disease, Angioedema
Deployment o the Multidisciplinary Prospective Cohort Imminent
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and…
- Conditions
- Chronic Inflammatory Disease, Angioedema, Severe Asthma, Lupus
- Trial name
- IMMINeNT (NCT04334031)
- Testing
- Biobanking with genetic analysis, SF-12 questionnaire
- Where
- France
- Volunteers
- 2,200 people
- Sponsor
- University Hospital, Lille
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal.
- Conditions
- Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
- Trial name
- NCT06339177
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis (MS), Myasthenia Gravis (MG)
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard…
- Conditions
- Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
- Trial name
- NCT07676266
- Testing
- CD20/BCMA-directed CAR-T cells Autologous 2nd generation
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Systemic Lupus Erythematosus
Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus
The purpose of this study is to determine whether Duloxetine (cymbalta) can reduce pain severity in patient with Systemic Lupus Erythematosus.
- Trial name
- NCT01269866
- Testing
- Cymbalta
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Jesus Gutierrez Stone
Systemic Lupus Erythematosus, Critical Illness
Accuracy, Feasibility and Acceptance of CGM Lupus
This is a prospective monocenter, non-randomised, open-lable single-group intervention diagnostic trial on the accuracy, reliability and feasibility of the continuous glucose monitoring system in critically systemic lupus…
- Conditions
- Systemic Lupus Erythematosus, Critical Illness, Diabetic Blood Glucose Monitoring
- Trial name
- NCT03296995
- Testing
- Flash glucose monitoring system
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus, Atherosclerosis
Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)
Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis. Endothelial dysfunction is the earliest marker of atherosclerosis and is measured by flow mediated dilation (FMD) of the brachial artery.
- Trial name
- MISSILE (NCT01101802)
- Testing
- Mycophenolate mofetil, sugar pill
- Where
- United Kingdom
- Volunteers
- 71 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Connective Tissue Diseases, Systemic Sclerosis
Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)
Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of connective tissue diseases including systemic sclerosis and systemic lupus erythematosus.
- Conditions
- Connective Tissue Diseases, Systemic Sclerosis, Systemic Lupus Erythematosus
- Trial name
- PAH (NCT03446339)
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- The University of Hong Kong
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Trial name
- IXchange (NCT03895801)
- Testing
- IFX-1, Glucocorticoid (GC)
- Where
- 76 sites in Belgium, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- InflaRx GmbH
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06980597
- Testing
- OL-108
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Beijing GoBroad Hospital
ANCA-associated Vasculitis
Abatacept in ANCA Associated Vasculitis
The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.
- Trial name
- ABAVAS (NCT00482066)
- Testing
- Abatacept (Orencia)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Systemic Lupus Erythematosus (SLE)
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-cluster of differentiation antigen 19 (CD19) chimeric antigen receptor (CAR) natural killer (NK) cells (KN5501) in patients with…
- Trial name
- NCT06010472
- Testing
- anti-CD19 CAR NK cells (KN5501)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changhai Hospital
Rheumatoid Arthritis, Polymyalgia Rheumatica
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
The purpose of this study is to determine wich treatment is the most effective in prevention of glucocorticoid-induced osteoporosis in patients with rheumatic diseases.
- Conditions
- Rheumatoid Arthritis, Polymyalgia Rheumatica, Giant Cell Arteritis, Polymyositis
- Trial name
- NCT00138983
- Testing
- Alendronate versus alfacalcidol (1-alpha OH vitamin D)
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Systemic Lupus Erythematosus, Systemic Sclerosis
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen…
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis, Polymyositis
- Trial name
- CASTLE (NCT06347718)
- Testing
- anti-CD19 CAR T cell therapy
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Miltenyi Biomedicine GmbH
Lupus Erythematosus, Systemic
Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
The purpose of this study is to evaluate whether a short interactive video game device is associated with performance on standard measures of attention and problem solving in patients with systemic lupus erythematosus(SLE).
- Trial name
- NCT03746197
- Testing
- Project EVO Multi- Treatment
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Jewish Health
Lupus Nephritis
The Iguratimod Effect on Lupus Nephritis (IGeLU)
This study is a 52-week, randomized, open, active-controlled trial of patients with active diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic agent iguratimod.
- Trial name
- IGeLU (NCT02936375)
- Testing
- Iguratimod, Cyclophosphamide, Azathioprine
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus
Anifrolumab Early Access Program
To provide early access (ie, before marketing authorisation) to anifrolumab 300 mg IV Q4W while receiving standard therapy in adult patients with moderate-to-severe active SLE
- Trial name
- AMANA (NCT04750057)
- Testing
- Anifrolumab
- Sponsor
- AstraZeneca
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
The purpose of this pilot study is to test whether an 8-week course of glucocorticoids, combined with rituximab, is effective in treating ANCA-associated vasculitis.
- Trial name
- SCOUT (NCT02169219)
- Testing
- Glucocorticoids, Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Systemic Lupus Erythematosus
Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
SLE(Systemic Lupus Erythematosus) is an autoimmune disese that primarily occurs in women(9:1 compared to men). The disease is activated by genetic and environmental factors, yet the female gender is the strongest risk factor.
- Trial name
- NCT00417430
- Testing
- ICI 182,780 (Faslodex)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology